Probiotics are increasingly used for diarrhea, but studies under the Food and Drug Administration and Investigational New Drug program are few. We conducted a phase-one placebo-controlled study of Lactobacillus reuteri DSM 17938 under Investigational New Drug program in 60 children 2-5 years of age (41 L. reuteri, 19 placebos) in a resource-constrained community in Peru. No differences in objective data on adverse events were noted, although some differences based on subjective parental reports for fever and diarrhea were seen.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557701PMC
http://dx.doi.org/10.1097/INF.0000000000002267DOI Listing

Publication Analysis

Top Keywords

lactobacillus reuteri
8
reuteri dsm
8
dsm 17938
8
children 2-5
8
2-5 years
8
years age
8
investigational drug
8
drug program
8
safety lactobacillus
4
17938 healthy
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!